N-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide
• 化学式: C₁₆H₂₀N₂O
• 分子量: 256.34
• InChiKey: ODFSOOCVJPIZNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS
  申请人：Bencherif Merouane

  公开号：US20110124678A1

  公开（公告）日：2011-05-26

  The present invention includes methods, uses, and selective α7 nAChR agonist compounds for treating or preventing metabolic disorders.

  本发明涉及用于治疗或预防代谢紊乱的方法、用途和选择性α7 nAChR激动剂化合物。
• TREATMENT WITH ALPHA7 SELECTIVE LIGANDS
  申请人：Bencherif Merouane

  公开号：US20110262407A1

  公开（公告）日：2011-10-27

  The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.

  本发明涉及用于治疗或预防刺激神经发生增殖有益的疾病和紊乱的方法、用途和选择性α7 nAChR配体。即，其中神经发生增殖的招募是治疗性的。
• TREATMENT WTH ALPHAT SELECTIVE LIGANDS
  申请人：TARGACEPT, INC.

  公开号：US20140234270A1

  公开（公告）日：2014-08-21

  The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.

  本发明涉及方法、用途和选择性α7 nAChR配体，用于治疗或预防刺激神经发生的疾病和障碍，即通过招募神经发生来进行治疗的疾病和障碍。
• Acrylamide derivatives as antirussive agent
  申请人：DOMPE' FARMACEUTICI S.p.A.

  公开号：EP0581165A2

  公开（公告）日：1994-02-02

  Acrylic amides having the formula wherein Ar represents a pyridyl radical or an optionally substituted benzyl radical; Ra represents hydrogen, lower alkyl, phenyl, cyano; Q represents the tropyl or quinuclidinyl radicals optionally N-oxo substituted, are described. The compounds of formula (I) show antitussive activity.

  丙烯酸酰胺的化学式为 其中 Ar 代表吡啶基或任选取代的苄基；Ra 代表氢、低级烷基、苯基、氰基；Q 代表任选被 N-氧代取代的托品基或喹啉基。 式（I）化合物具有抗呕吐活性。
• Treatment with alpha7-selective ligands
  申请人：Targacept, Inc.

  公开号：EP2409703A1

  公开（公告）日：2012-01-25

  The present invention relates to selective α7 nAChR agonist compounds for use in treating or preventing metabolic syndrome.

  本发明涉及用于治疗或预防代谢综合征的选择性 α7 nAChR 激动剂化合物。